Covid-19
The Covid-19 vaccine candidates by University of Oxford-AstraZeneca, Moderna Inc, Pfizer Inc-BioNTech and Chinese firm Sinovac & Sinopharm are all undergoing Phase III trials at present. Oxford-AstraZeneca coronavirus vaccine price:Adar Poonawalla, CEO of Serum Institute of India, said the cost of the vaccine is estimate...
The government has permitted icddr,b to run the Phase-III trial of a coronavirus vaccine developed by Chinese biopharmaceutical company Sinovac in Bangladesh.The Bangladesh Medical Research Council (BMRC) approved the vaccine in the middle of July more than a month after the icddr,b, local partner of Sinovac, submitted an application to...
Background: Biotech Company Novavax announced in March that it has produced a stable, prefusion protein nanoparticle vaccine candidate for COVID-19. A Phase 1/2 trial evaluating NVX-CoV2373 began on 25 May. Study Design: A randomized, observer-blinded, placebo-controlled trial of 130 healthy participants 18 to 59 years of age at two s...
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.NVX‑CoV2373 was created using Novavax’ recombinant nanop...
Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. Engineered from the genetic sequence of COVID-19, we used our recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. The company launched trials for a Covid-19 vaccine in May.Phase 1 & Phase 2 TrialIn t...
After the FDA’s issuance of an emergency use authorization (EUA) for the use of Covid-19 convalescent plasma (CCP), the Infectious Diseases Society of America (IDSA) and the World Health Organization (WHO) issued statements urging caution.
Both organizations agreed that using CCP may hold promise as a treatment for the virus but noted a lack of hi...
A 33-year-old man in Hong Kong may represent the first confirmed case of reinfection, researchers in Hong Kong said. He was reinfected with the novel coronavirus, but didn't develop any symptoms the second time. Viral sequence disparity indicates Hong Kong case not simply prolonged infection.
The man was diagnosed with COVID-19 on Marc...
Background: mRNA-1273 was developed by Moderna based on prior
studies of related coronaviruses such as those that cause severe acute
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A
Phase 1 trial (NCT04283461) of 105 healthy participants provided the basis for
Moderna’s investigational new drug appl...
Moderna’s mRNA vaccine technology
offers potential advantages in efficacy, speed of development, and production
scalability and reliability.
mRNA-based vaccines offer several
advantages, including:
Ability
to mimic many aspects of natural viral infections.
mRNA enters cells and is used to
produce viral antigen...
The vaccine, known as mRNA-1273,
was co-developed by the Cambridge, Massachusetts-based American biotechnology
company Moderna, Inc., and the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health. The trial, which
will be conducted at U.S. clinical research sites, is expecte...
What is herd immunity?
When most of a population is immune to an infectious
disease, this provides indirect protection—or herd immunity (also called herd
protection)—to those who are not immune to the disease.Sponsored content
Background: The Oxford Vaccine Group at the University of Oxford
are developing a new vaccine candidate for COVID-19, a chimpanzee adenovirus
vaccine vector called AZD1222 (previously ChAdOx1). The team has previously
developed a MERS vaccine.
In India, the candidate is being
jointly developed by the Serum Institute of India...
